

UCSF

UC San Francisco Previously Published Works

Title

The Relationship Between Hippocampal Volumes and Delayed Recall Is Modified by APOE ε4 in Mild Cognitive Impairment

Permalink

<https://escholarship.org/uc/item/7f12p4bk>

Authors

Wang, Xiwu
Zhou, Wenjun
Ye, Teng
et al.

Publication Date

2019

DOI

10.3389/fnagi.2019.00036

Peer reviewed



The Relationship Between Hippocampal Volumes and Delayed Recall Is Modified by APOE ϵ 4 in Mild Cognitive Impairment

OPEN ACCESS

Xiwu Wang¹, Wenjun Zhou², Teng Ye³, Xiaodong Lin^{1*}, Jie Zhang^{4*} and the Alzheimer's Disease Neuroimaging Initiative[†]

Edited by:

Panteleimon Giannakopoulos,
Université de Genève, Switzerland

Reviewed by:

Ramesh Kandimalla,
Texas Tech University Health
Sciences Center, United States
Sven Haller,
Affidea CDRC, Switzerland

*Correspondence:

Xiaodong Lin
13325779718@163.com
Jie Zhang
jayzhang1014@gmail.com

[†]Data used in preparation of this article were obtained from the Alzheimer's Disease Neuroimaging Initiative (ADNI) database (adni.loni.usc.edu). As such, the investigators within the ADNI contributed to the design and implementation of ADNI and/or provided data but did not participate in analysis or writing of this report. A complete listing of ADNI investigators can be found at: http://adni.loni.usc.edu/wp-content/uploads/how_to_apply/ADNI_Acknowledgement_List.pdf

Received: 11 December 2018

Accepted: 06 February 2019

Published: 26 February 2019

Citation:

Wang X, Zhou W, Ye T, Lin X, Zhang J and the Alzheimer's Disease Neuroimaging Initiative (2019) The Relationship Between Hippocampal Volumes and Delayed Recall Is Modified by APOE ϵ 4 in Mild Cognitive Impairment. *Front. Aging Neurosci.* 11:36. doi: 10.3389/fnagi.2019.00036

¹ Department of Psychiatry, Wenzhou Seventh People's Hospital, Wenzhou, China, ² Department of Pathology, Hangzhou Normal University, Hangzhou, China, ³ Department of Ultrasound, The First Affiliated Hospital of Wenzhou Medical University, Wenzhou, China, ⁴ Independent Researcher, Hangzhou, China

Objective: To investigate whether APOE ϵ 4 affects the association of verbal memory with neurodegeneration presented by the hippocampal volume/intracranial volume ratio (HpVR).

Methods: The study sample included 371 individuals with normal cognition (NC), 725 subjects with amnesic mild cognitive impairment (aMCI), and 251 patients with mild Alzheimer's disease (AD) from the Alzheimer's Disease Neuroimaging Initiative (ADNI) who underwent the rey auditory verbal learning test (RAVLT). Multiple linear regression models were conducted to assess the effect of the APOE ϵ 4*HpVR interaction on RAVLT in all subjects and in each diagnostic group adjusting for age, gender and educational attainment, and global cognition.

Results: In all subjects, there was no significant APOE ϵ 4 \times HpVR interaction for immediate recall or delayed recall ($p > 0.05$). However, in aMCI subjects, there was a significant APOE ϵ 4 \times HpVR interaction for delayed recall ($p = 0.008$), but not immediate recall ($p = 0.15$). More specifically, the detrimental effect of APOE ϵ 4 on delayed recall altered by HpVR such that this effect was most evident among subjects with small to moderate HpVR, but this disadvantage was absent or even reversed among subjects with larger HpVR. No significant interaction was observed in the NC or AD group.

Conclusion: These findings highlight a potential role of APOE ϵ 4 status in affecting the association of hippocampus size with delayed recall memory in the early stage of AD.

Keywords: Alzheimer's disease, amnesic mild cognitive impairment, hippocampus, episodic memory, APOE ϵ 4

INTRODUCTION

The effect of the apolipoprotein E ϵ 4 (APOE ϵ 4) allele on cognitive abilities is complicated. Previous studies demonstrated the diverse roles of APOE ϵ 4 allele in cognitive abilities dependent on different ages. In young populations, the APOE ϵ 4 allele has a beneficial effect on learning and memory ability. However, the APOE ϵ 4 allele is also associated with the decline of learning and

memory ability in old subjects (Han and Bondi, 2008; Caselli et al., 2009; Tuminello and Han, 2011). These interesting findings have been conceptualized as the APOE antagonistic pleiotropy hypothesis (Han and Bondi, 2008; Caselli et al., 2009; Tuminello and Han, 2011).

The hippocampus is critical for episodic memory function and its size is considered as an index of the degree of cognitive decline (Kilpatrick et al., 1997; Eldridge et al., 2000; Ystad et al., 2009). A previous study also showed that the APOE $\epsilon 4$ allele contributes to the reduction of hippocampal volume in patients with mild cognitive impairment (MCI) and Alzheimer's disease (AD) (Khan et al., 2017). Additionally, APOE $\epsilon 4$ was found to reduce hippocampal volumes and impair episodic memory in a dose-dependent manner (APOE $\epsilon 4$ homozygous > APOE $\epsilon 4$ heterozygous > APOE $\epsilon 4$ non-carriers) (Liu et al., 2016). A recent study revealed that hippocampal volume was positively associated with episodic memory in cognitively normal old individuals with APOE $\epsilon 4$ homozygotes (Lim et al., 2017). However, it is unknown whether the APOE $\epsilon 4$ allele also has antagonistic pleiotropic effects on the association of hippocampal volumes with episodic memory across the AD continuum. Our primary goal was to examine whether the APOE $\epsilon 4$ allele modulates the relationship between hippocampal volumes and verbal memory in subjects with NC, MCI, and mild AD from the Alzheimer's disease neuroimaging initiative (ADNI) dataset.

MATERIALS AND METHODS

Alzheimer's Disease Neuroimaging Initiative

Demographic and imaging data used in the preparation of this study were extracted from the ADNI database¹ in January 2017. The primary aim of the ADNI has been to test whether clinical and neuropsychological assessment, neuroimaging and other biomarkers can be integrated to predict the progression of MCI and early AD. The ADNI was conducted after institutional review board approval at each site. Written informed consent was obtained from all participants or their authorized representatives. Our study sample included subjects who had hippocampal volumetric, verbal memory and APOE 4 ϵ genotype data available from one visit cycle ($n = 1347$). In this study, there were 371 subjects with NC, 725 patients with aMCI, and 251 patients with AD.

Diagnosis Criteria

Inclusive and exclusive criteria can be found in detail at <http://www.adni-info.org>. The NC group had a score of at least 24 on the mini-mental state examination (MMSE) and a score of 0 on the Clinical Dementia Rating (CDR) scale (Petersen et al., 2010). The aMCI group had a score of 24 or higher on the MMSE, a CDR score of 0.5, a subjective memory complaint, objective memory impairment as examined by the Logical Memory II subscale of the Wechsler Memory Scale–Revised (Wechsler, 1987), essentially

preserved activities of daily living, and were not demented (Petersen et al., 2010). The AD group met the National Institute of Neurological and Communicative Disorders and Stroke and AD and Related Disorders Association criteria for probable AD, having scores from 20 to 26 on the MMSE and a score of 0.5 or 1 on the CDR (Petersen et al., 2010).

Neuropsychological Outcomes

The MMSE and CDR were used to evaluate global cognitive function and dementia severity, respectively. The Rey auditory verbal learning test (RAVLT) (Schmidt, 1996) was applied to measure verbal memory. The immediate recall scores (range, 0–75) and delayed recall scores (range, 0–15) were utilized as our main evaluation indicators.

Structural Magnetic Resonance Imaging

Structural MRI brain scans were obtained using 1.5T MRI scanners with a standardized protocol, which is described in detail at www.loni.ucla.edu/ADNI. Hippocampal volume

TABLE 1 | Overall sample characteristics by diagnostic groups.

Characteristics	Controls ($n = 371$)	aMCI ($n = 725$)	AD ($n = 251$)	<i>P</i> value
Age, y	74.7 (5.6)	72.6 (7.4) ^b	74.7 (8.0)	<0.001
Gender, % male	50.9	58.1	56.2	0.079
APOE $\epsilon 4$, % positive	26.1 ^a	50.5 ^b	68.9 ^c	<0.001
Education, y	16.2 (2.7)	15.9 (2.9)	15.2 (2.9) ^c	<0.001
MMSE, score	29.1 (1.1) ^a	27.6 (1.8) ^b	23.1 (2) ^c	<0.001
RAVLT immediate recall	44.5 (9.8) ^a	34.8 (10.8) ^b	23.3 (7.1) ^c	<0.001
RAVLT delayed recall	5.8 (2.3) ^a	4.3 (2.5) ^b	2.0 (1.6) ^c	<0.001
Hippocampal volume, mm ³	7355 (907) ^a	6787 (1137) ^b	5789 (1032) ^c	<0.001
HpVr	4.9 (0.6) ^a	4.4 (0.8) ^b	3.8 (0.7) ^c	<0.001

MMSE, mini-mental state examination; RAVLT, rey auditory verbal learning test; aMCI, amnesic mild cognitive impairment; AD, Alzheimer's disease; HpVr, hippocampal volume ratio (hippocampal/intracranial volume \times 1000). Data are summarized as mean (SD). Alphabetic "a," "b," and "c" superscripts show that the pairwise groups have statistical significance using the Tukey HSD.

TABLE 2 | Association between RAVLT and HpVr in three diagnostic groups.

	HpVr							
	All subjects		Controls		aMCI		AD	
	<i>r</i>	<i>p</i>	<i>r</i>	<i>p</i>	<i>r</i>	<i>p</i>	<i>r</i>	<i>p</i>
Immediate recall	0.485	<0.001	0.117	0.024	0.414	<0.001	0.152	0.016
Delayed recall	0.413	<0.001	0.044	0.4	0.341	<0.001	0.229	<0.001

RAVLT, rey auditory verbal learning test; aMCI, amnesic mild cognitive impairment; AD, Alzheimer's disease; HpVr, hippocampal volume ratio (hippocampal/intracranial volume \times 1000).

¹<http://adni.loni.usc.edu>

measures were performed using FreeSurfer software². In order to correct for subject differences in head size, hippocampal volumes were normalized by individual intracranial volume (formula: hippocampal/intracranial volume $\times 10^3$). The MRI volumes of brain structures used in this study were extracted from UCSF data in the ADNI dataset³.

²<http://surfer.nmr.mgh.harvard.edu>

³<https://ida.loni.usc.edu/pages/access/studyData.jsp>

TABLE 3 | RAVLT and HpVR by diagnostic groups and APOE $\epsilon 4$ status.

	APOE $\epsilon 4$ -	APOE $\epsilon 4$ +	<i>p</i> value
All subjects			
RAVLT immediate recall	38.0 (12.1)	32.3 (11.7)	<0.001
RAVLT delayed recall	4.8 (2.6)	3.7 (2.6)	<0.001
HpVR	4.6 (0.8)	4.3 (0.8)	<0.001
Controls			
RAVLT immediate recall	44.4 (9.4)	44.8 (10.6)	0.759
RAVLT delayed recall	5.9 (2.2)	5.7 (2.5)	0.47
HpVR	4.9 (0.6)	4.9 (0.7)	0.656
aMCI			
RAVLT immediate recall	36.3 (11.4)	33.3 (10.1)	<0.001
RAVLT delayed recall	4.6 (2.5)	4.0 (2.6)	0.001
HpVR	4.53 (0.8)	4.36 (0.8)	0.005
AD			
RAVLT immediate recall	23.4 (7.0)	23.3 (7.1)	0.92
RAVLT delayed recall	2.2 (1.8)	2.0 (1.5)	0.218
HpVR	3.9 (0.8)	3.7 (0.6)	0.031

RAVLT, *rey auditory verbal learning test*; aMCI, *amnestic mild cognitive impairment*; AD, *Alzheimer's disease*; HpVR, *hippocampal volume ratio (hippocampal/intracranial volume $\times 1000$)*.

APOE Genotyping

The data of APOE genotypes of our study sample were extracted from the ADNI database. Further information can be found at adni.loni.usc.edu. Participants were classified as APOE $\epsilon 4$ -negative (-) if they carried no APOE $\epsilon 4$ allele or APOE $\epsilon 4$ -positive (+) if they carried at least one APOE $\epsilon 4$ allele.

Statistical Analysis

Socio-demographics and clinical outcomes were compared between diagnostic groups using analysis of variance (ANOVA) for continuous variables and chi-squared for categorical variables in all subjects and within diagnostic groups. The relationship between HpVR and memory outcomes was analyzed by Pearson correlation analysis in all subjects and within diagnostic groups. HpVR and memory outcomes were compared between APOE $\epsilon 4$ carriers and non-carriers using student's *t* test in all subjects and within diagnostic groups. The multivariable linear regression was performed to evaluate the independent and interactive relationship of APOE $\epsilon 4$ status and HpVR on verbal memory performance (RAVLT immediate and delayed recall scores) in all subjects and within diagnostic groups. In model 1, we evaluated the independent effects of APOE $\epsilon 4$ status and HpVR. Then, the HpVR \times APOE $\epsilon 4$ status interaction was added to model 2, but was eliminated if not significant ($p > 0.05$). All analyses were adjusted for age, gender, education, MMSE scores and diagnosis (only in the overall sample analysis). The resultant *p*-values for the associations of the APOE $\epsilon 4$ * HpVR interaction with memory performance were corrected for multiple comparisons with false discovery rate (FDR) (Benjamini and Hochberg, 1995). IBM SPSS version 20 was used to perform all statistical analyses. A two-tailed *P* value of less than 0.05 was considered to be statistically significant.

TABLE 4 | Results of multivariable linear regression analyses modeling the independent and interactive effects of APOE $\epsilon 4$ status and HpVR on verbal memory performance.

Sample/outcome	Multivariable linear regression models					
	Model 1: No interactions in model				Model 2: Interaction included in model, APOE $\epsilon 4$ status*HpVR	
	APOE $\epsilon 4$ status (- vs. +)		HpVR		B (SE)	<i>P</i> value
	B (SE)	<i>P</i> value	B (SE)	<i>P</i> value		
Overall sample						
Immediate recall	-1.2 (0.5)	0.016	2.2 (0.37)	<0.001	0.7 (0.6)	0.26
Delayed recall	-0.3 (0.1)	0.017	0.6 (0.1)	<0.001	0.3 (0.2)	0.091
Controls						
Immediate recall	-0.3 (1.1)	0.8	-0.3 (0.9)	0.7	0.4 (1.7)	0.8
Delayed recall	-0.3 (0.3)	0.3	-0.1 (0.2)	0.6	-0.6 (0.4)	0.2
aMCI						
Immediate recall	-1.8 (0.7)	0.006	3.1 (0.5)	<0.001	1.2 (0.8)	0.15
Delayed recall	-0.3 (0.2)	0.088	0.8 (0.1)	<0.001	0.6 (0.2)	0.008
AD dementia						
Immediate recall	0.3 (0.9)	0.7	0.6 (0.8)	0.4	-0.4 (1.3)	0.77
Delayed recall	-0.2 (0.2)	0.34	0.4 (0.2)	0.014	-0.1 (0.3)	0.66

AD, *Alzheimer disease*; aMCI, *amnestic mild cognitive impairment*; B, *unstandardized regression coefficient*; HpVR, *hippocampal volume ratio (hippocampal/intracranial volume $\times 1000$)*. All analyses were adjusted for age, sex, education, MMSE scores, and diagnostic group (overall sample only).

RESULTS

Socio-Demographic Data

Table 1 listed the socio-demographic characteristics of the subjects. Several demographic and clinical variables differed significantly across the three diagnostic groups (Table 1).


Association of HpVR With RAVLT

To examine the relationships between HpVR and RAVLT immediate and delayed recall scores, Pearson correlation tests were performed in all subjects and within three diagnostic groups (Table 2). As expected, positive correlations between HpVR and RAVLT immediate ($r = 0.485, p < 0.001$) and delayed ($r = 0.413, p < 0.001$) recall scores were found in all subjects. In diagnosis-stratified analyses, a positive correlation between

HpVR and immediate recall ($r = 0.117, p = 0.024$), but not delayed recall ($r = 0.044, p = 0.4$), was observed in controls. In agreement with findings in the whole sample, HpVR was positively correlated with immediate recall ($r = 0.414, p < 0.001$), and delayed recall ($r = 0.341, p < 0.001$) scores in subjects with MCI. Among subjects with AD dementia, HpVR was correlated with immediate recall ($r = 0.152, p = 0.016$), and delayed recall ($r = 0.229, p < 0.001$) scores.

Effect of APOE $\epsilon 4$ Genotypes on HpVR and RAVLT

In the overall sample, APOE $\epsilon 4$ carriers had lower RAVLT immediate and delayed recall scores and smaller hippocampal volumes compared to non-carriers (Table 3). In diagnosis-stratified analyses, APOE $\epsilon 4$ carriers had lower RAVLT




immediate and delayed recall scores in the MCI group, but not the NC or AD group. Further, compared with non-carriers, APOE $\epsilon 4$ carriers had smaller hippocampal volumes in the MCI and AD groups, but not the NC group.

Linear Regression Results

In all subjects, there was no significant HpVR by APOE $\epsilon 4$ status interaction for immediate recall ($p = 0.26$; **Table 4**) or delayed recall ($p = 0.091$; **Table 4** and **Figure 1A**). In diagnosis-stratified analyses, the HpVR by APOE $\epsilon 4$ status interaction was significant for delayed recall in an aMCI group ($p = 0.008$), but not immediate recall ($p = 0.15$). More specifically, the association between HpVR and delayed recall was stronger in APOE $\epsilon 4$ carriers compared to non-carriers. **Figure 1C** shows that APOE $\epsilon 4$ carriers outperform non-carriers on delayed recall memory among subjects with large HpVR (right side of the x-axis) but this advantage gradually disappears

and reverses to confer memory deficits among subjects with moderate to small HpVR (left side of the x-axis). However, the association of the APOE4*HpVR interaction with delayed recall scores in the MCI group did not survive FDR correction ($p = 0.096$). The HpVR by APOE $\epsilon 4$ status interaction for immediate recall and delayed recall was not significant in the control or in the AD dementia group (all $p > 0.05$, **Table 4** and **Figures 1B,D**). Among controls, no significant difference in immediate ($p = 0.8$) or delayed recall ($p = 0.3$) was found between APOE $\epsilon 4$ carriers and non-carriers, and HpVR was not associated with immediate recall ($p = 0.7$) or delayed recall ($p = 0.6$) (**Table 4**). In AD dementia, no significant difference in immediate ($p = 0.7$) and delayed recall ($p = 0.34$) was found between APOE $\epsilon 4$ carriers and non-carriers. In AD dementia, larger HpVR was associated with better delayed recall ($p = 0.014$), but not with immediate recall ($p = 0.4$).



In addition, we also examined the effect of the left-HpVR/Right-HpVR*APOE ϵ 4 interaction on RAVLT immediate and delayed recall scores (see **Figures 2, 3** and **Tables 5, 6**). Similarly, a significant left-HpVR*APOE ϵ 4 interaction for delayed recall among MCI subjects was observed ($p = 0.004$), while the association did not survive FDR correction ($p = 0.096$). Further, there was a significant right-HpVR*APOE ϵ 4 interaction for delayed recall among MCI subjects ($p = 0.034$), but the association did not survive FDR correction ($p = 0.27$).

DISCUSSION

In the present study, we examined the effect of the APOE ϵ 4 allele on the interplay between episodic memory and hippocampal volume in the three diagnostic groups (controls, aMCI, mild AD). Our study found an interesting fact that, depending on different

hippocampal volumes, the APOE ϵ 4 allele asserts different effects on delayed recall. Our data suggested that the deleterious effect of APOE ϵ 4 on delayed recall altered by HpVR such that this effect was most evident among aMCI patients with small to moderate HpVR, but this disadvantage was absent or even reversed among aMCI patients with larger HpVR, indicating the dual effects of APOE ϵ 4 on the association of delayed recall memory and hippocampal volumes.

Antagonistic pleiotropy (Williams, 1957) posits that certain genes or alleles may affect fitness (for instance, survival, and reproduction) differentially at different ages. Recently, the antagonistic pleiotropy hypothesis of APOE has been proposed by some researchers based on findings that the impact of the APOE ϵ 4 allele on cognitive functioning, episodic memory in particular, may be beneficial at younger ages, while it appears detrimental in later life (Han and Bondi, 2008; Caselli et al., 2009; Tuminello and Han, 2011; Jochemsen et al., 2012).




TABLE 5 | Results of multivariable linear regression analyses modeling the independent and interactive effects of APOE ϵ 4 status and left-HpVR on verbal memory performance.

Sample/outcome	Multivariable linear regression models					
	Model 1: No interactions in model				Model 2: Interaction included in model, APOE ϵ 4 status*Left- HpVR	
	APOE ϵ 4 status (– vs. +)		Left-HpVR		B (SE)	P value
B (SE)	P value	B (SE)	P value			
Overall sample						
Immediate recall	–1.2 (0.5)	0.16	4.3 (0.7)	<0.001	1.6 (1.2)	0.17
Delayed recall	–0.3 (0.13)	0.15	1.2 (0.18)	<0.001	0.6 (0.3)	0.054
Controls						
Immediate recall	–0.2 (1.1)	0.8	–0.2 (1.6)	0.883	0.02 (3.3)	0.996
Delayed recall	–0.3 (0.3)	0.3	–0.1 (0.4)	0.8	–1 (0.8)	0.2
aMCI						
Immediate recall	–1.9 (0.7)	0.006	6 (0.9)	<0.001	2.6 (1.6)	0.1
Delayed recall	–0.3 (0.18)	0.072	1.5 (0.2)	<0.001	1.2 (0.4)	0.004
AD dementia						
Immediate recall	0.4 (0.9)	0.7	1.5 (1.5)	0.3	0.6 (2.6)	0.8
Delayed recall	–0.16 (0.2)	0.47	1.2 (0.3)	0.001	–0.3 (0.6)	0.6

AD, Alzheimer disease; aMCI, amnesic mild cognitive impairment; B, unstandardized regression coefficient; HpVR, hippocampal volume ratio (hippocampal/intracranial volume \times 1000). All analyses were adjusted for age, sex, education, MMSE scores, and diagnostic group (overall sample only).

TABLE 6 | Results of multivariable linear regression analyses modeling the independent and interactive effects of APOE ϵ 4 status and Right-HpVR on verbal memory performance.

Sample/outcome	Multivariable linear regression models					
	Model 1: No interactions in model				Model 2: Interaction included in model, APOE ϵ 4 status*Right-HpVR	
	APOE ϵ 4 status (– vs. +)		Right-HpVR		B (SE)	P value
B (SE)	P value	B (SE)	P value			
Overall sample						
Immediate recall	–1.2 (0.5)	0.015	3.8 (0.7)	<0.001	1 (1.1)	0.37
Delayed recall	–0.3 (0.1)	0.11	0.9 (0.17)	<0.001	0.3 (0.3)	0.25
Controls						
Immediate recall	–0.2 (1.1)	0.8	–0.2 (1.6)	0.9	1 (3)	0.7
Delayed recall	–0.3 (0.3)	0.3	–0.4 (0.4)	0.37	–1.3 (0.8)	0.09
aMCI						
Immediate recall	–1.8 (0.7)	0.007	5.6 (0.9)	<0.001	2 (1.6)	0.2
Delayed recall	–0.3 (0.18)	0.088	1.4 (0.2)	<0.001	0.9 (0.4)	0.034
AD dementia						
Immediate recall	0.2 (0.9)	0.8	0.5 (1.3)	0.7	–2 (2.4)	0.4
Delayed recall	–0.3 (0.2)	0.2	0.4 (0.3)	0.2	–0.2 (0.6)	0.7

AD, Alzheimer disease; aMCI, amnesic mild cognitive impairment; B, unstandardized regression coefficient; HpVR, hippocampal volume ratio (hippocampal/intracranial volume \times 1000). All analyses were adjusted for age, sex, education, MMSE scores, and diagnostic group (overall sample only).

However, concomitant underlying mechanisms of these changes remain unclear. Increasing evidence suggested that APOE ϵ 4 carriers may primarily recruit greater compensatory resources to maintain equivalent or superior levels of memory performance as APOE ϵ 4 non-carriers. Nevertheless, once AD pathological burdens sufficiently accumulate, APOE ϵ 4 carriers' compensatory recruitment will fail to sustain memory performance and memory decline ensues (Han and Bondi, 2008). For instance, one study (Bookheimer et al., 2000) using fMRI techniques

suggested that APOE ϵ 4 carriers, in non-demented older people, showed greater activation in the hippocampus and other brain regions during the encoding portion of a memory task, providing evidence for APOE ϵ 4 carriers' compensatory recruitment. In other words, APOE ϵ 4 carriers may more greatly activate memory-related brain regions to sustain the same or better level of cognitive performance as APOE ϵ 4 non-carriers. Dickerson et al. (2005) also reported findings supportive of APOE ϵ 4 carriers' compensatory recruitment in

three diagnostic groups, including cognitively normal older people and patients with MCI or AD. They found that APOE ϵ 4 carriers, irrespective of diagnosis, showed increased hippocampal activity during the encoding portion of a face-name task. Similarly, a more recent study suggested that APOE ϵ 4 carriers recruited additional neural resources to successfully complete a challenging working memory task (Scheller et al., 2017). However, once the compensatory recruitment of neural resources fails, memory may begin to decline (Han and Bondi, 2008; Tuminello and Han, 2011). Most cross-sectional studies have supported the idea that APOE ϵ 4 carriers in older people performed more poorly than non-carriers in episodic memory tasks (Honea et al., 2009; Adamson et al., 2010; Kukolja et al., 2010), while not universally the case (Welsh-Bohmer et al., 2009). Furthermore, one important study by Caselli et al. (2009) longitudinally followed individuals ranging from 21 to 97 years of age. They found that memory decline in APOE ϵ 4 carriers started before 60 years of age and showed a steeper rate of memory decline compared to non-carriers, indicating that the detrimental effects of APOE ϵ 4 on episodic memory may become evident around the age of 60 years. Similarly, based on our findings (Figure 1C), APOE ϵ 4 carriers in the aMCI group, despite similar hippocampal volumes, outperformed non-carriers on episodic memory among subjects with large HpVR (HpVR > approximately 5.2, referring to the compensatory recruitment state). Once AD pathological burdens sufficiently accrue (such as hippocampal atrophy), this APOE ϵ 4 advantage was not evident and gradually reversed to confer memory deficits among subjects with moderate to small HpVR (HpVR < approximately 5.2, referring to the failure of compensatory recruitment). Our data indicated that APOE ϵ 4 carriers as an at-risk population for AD may benefit from drug or non-drug interventions that are tailored to the levels of hippocampal atrophy. After acquisition of APOE ϵ 4 genotype and hippocampal volume data, APOE ϵ 4 carriers could be further targeted by some interventions to maintain memory performance at this paramount turning point.

Our findings have several important implications. The dual effects of APOE ϵ 4 on the association of delayed recall memory with hippocampal volumes are clinically critical because delayed recall memory is used to diagnose aMCI and AD dementia (Albert et al., 2011; McKhann et al., 2011; Dubois et al., 2014) and norms of episodic memory tests are currently not APOE ϵ 4-adjusted. Therefore, this may lead to some misdiagnoses if we do not take APOE ϵ 4 status into consideration. For instance, due to our findings (Figure 1C), a true aMCI diagnosis may be more likely to be delayed in APOE ϵ 4 carriers than non-carriers in individuals with HpVR > approximately 5.2, because beneficial effects of APOE ϵ 4 on episodic memory in these subjects may mask underlying AD neuropathology, particularly in the earlier stages of disease.

There are several potential limitations in the present study. First, the cross-sectional design prevents us from determining temporality in the association between episodic memory and HpVR. In this cross-section analysis, we also could not measure rates of memory decline in APOE ϵ 4 carriers vs. non-carriers. Longitudinal studies are needed to more accurately test the

hypothesis that APOE ϵ 4 status may modulate the relationship between hippocampus volumes and episodic memory. Second, the APOE antagonistic pleiotropy hypothesis proposes that the APOE ϵ 4 allele is linked to better cognitive functioning in young adulthood and then it reverses to confer cognitive deficits in older age. However, in the current study, the lack of younger people limits our test of the APOE antagonistic pleiotropy hypothesis. Third, the HpVR by APOE ϵ 4 interaction for memory testing was not significant in the control or in the AD dementia group. One potential explanation may be due to the fact that the variability of memory scores and hippocampal volumes may be low in controls, and memory scores and hippocampal volumes may have reached a plateau in AD patients. Finally, after FDR correction, a marginally significant two-way APOE ϵ 4*HpVR interaction for delayed recall in MCI subjects was observed ($p = 0.096$), and thus this finding requires replication.

In summary, our study highlights the potential role of APOE ϵ 4 in affecting the relationship between hippocampus volumes and delayed recall memory in MCI patients.

DATA AVAILABILITY

Publicly available datasets were analyzed in this study. This data can be found here: <http://adni.loni.usc.edu/>.

ETHICS STATEMENT

All subjects gave signed, informed consent to participate in the study. Clinical research described in the manuscript was carried out in accordance with Declaration of Helsinki promulgated by the National Institute of Health.

AUTHOR CONTRIBUTIONS

JZ and XL conceived and designed the study. XW, WZ, and TY performed the research, analyzed the data, and wrote the manuscript.

FUNDING

Data collection and sharing for this project was funded by the Alzheimer's Disease Neuroimaging Initiative (ADNI) (National Institutes of Health Grant U01 AG024904) and DOD ADNI (Department of Defense award number W81XWH-12-2-0012). ADNI was funded by the National Institute on Aging, the National Institute of Biomedical Imaging and Bioengineering, and through generous contributions from the following: AbbVie, Alzheimer's Association; Alzheimer's Drug Discovery Foundation; Araclon Biotech; BioClinica, Inc.; Biogen; Bristol-Myers Squibb Company; CereSpir, Inc.; Cogstate; Eisai Inc.; Elan Pharmaceuticals, Inc.; Eli Lilly and Company; EuroImmun; F. Hoffmann-La Roche Ltd and its affiliated company Genentech, Inc.; Fujirebio; GE Healthcare; IXICO Ltd.; Janssen Alzheimer Immunotherapy Research & Development, LLC.; Johnson

& Johnson Pharmaceutical Research & Development LLC.; Lumosity; Lundbeck; Merck & Co., Inc.; Meso Scale Diagnostics, LLC.; NeuroRx Research; Neurotrack Technologies; Novartis Pharmaceuticals Corporation; Pfizer Inc.; Piramal Imaging; Servier; Takeda Pharmaceutical Company; and Transition Therapeutics. The Canadian Institutes of Health Research is providing funds to support ADNI clinical sites in Canada.

Private sector contributions are facilitated by the Foundation for the National Institutes of Health (www.fnih.org). The grantee organization is the Northern California Institute for Research and Education, and the study is coordinated by the Alzheimer's Therapeutic Research Institute at the University of Southern California. ADNI data are disseminated by the Laboratory for Neuro Imaging at the University of Southern California.

REFERENCES

- Adamson, M. M., Landy, K. M., Duong, S., Fox-Bosetti, S., Ashford, J. W., Murphy, G. M., et al. (2010). Apolipoprotein E epsilon4 influences on episodic recall and brain structures in aging pilots. *Neurobiol. Aging* 31, 1059–1063. doi: 10.1016/j.neurobiolaging.2008.07.017
- Albert, M. S., Dekosky, S. T., Dickson, D., Dubois, B., Feldman, H. H., Fox, N. C., et al. (2011). The diagnosis of mild cognitive impairment due to Alzheimer's disease: recommendations from the national institute on aging-Alzheimer's association workgroups on diagnostic guidelines for Alzheimer's disease. *Alzheimers Dement.* 7, 270–279. doi: 10.1016/j.jalz.2011.03.008
- Benjamini, Y., and Hochberg, Y. (1995). Controlling the false discovery rate: a practical and powerful approach to multiple testing. *J. R. Stat. Soc. Series B Stat. Methodol.* 57, 289–300. doi: 10.1111/j.2517-6161.1995.tb02031.x
- Bookheimer, S. Y., Strojwas, M. H., Cohen, M. S., Saunders, A. M., Pericak-Vance, M. A., Mazziotta, J. C., et al. (2000). Patterns of brain activation in people at risk for Alzheimer's disease. *N. Engl. J. Med.* 343, 450–456. doi: 10.1056/NEJM200008173430701
- Caselli, R. J., Dueck, A. C., Osborne, D., Sabbagh, M. N., Connor, D. J., Ahern, G. L., et al. (2009). Longitudinal modeling of age-related memory decline and the APOE epsilon4 effect. *N. Engl. J. Med.* 361, 255–263. doi: 10.1056/NEJMoa0809437
- Dickerson, B. C., Salat, D. H., Greve, D. N., Chua, E. F., Rand-Giovannetti, E., Rentz, D. M., et al. (2005). Increased hippocampal activation in mild cognitive impairment compared to normal aging and AD. *Neurology* 65, 404–411. doi: 10.1212/01.wnl.0000171450.97464.49
- Dubois, B., Feldman, H. H., Jacova, C., Hampel, H., Molinuevo, J. L., Blennow, K., et al. (2014). Advancing research diagnostic criteria for Alzheimer's disease: the IWG-2 criteria. *Lancet Neurol.* 13, 614–629. doi: 10.1016/S1474-4422(14)70090-0
- Eldridge, L. L., Knowlton, B. J., Furmanski, C. S., Bookheimer, S. Y., and Engel, S. A. (2000). Remembering episodes: a selective role for the hippocampus during retrieval. *Nat. Neurosci.* 3, 1149–1152. doi: 10.1038/80671
- Han, S. D., and Bondi, M. W. (2008). Revision of the apolipoprotein E compensatory mechanism recruitment hypothesis. *Alzheimers Dement.* 4, 251–254. doi: 10.1016/j.jalz.2008.02.006
- Honea, R. A., Vidoni, E., Harsha, A., and Burns, J. M. (2009). Impact of APOE on the healthy aging brain: a voxel-based MRI and DTI study. *J. Alzheimers Dis.* 18, 553–564. doi: 10.3233/JAD-2009-1163
- Jochemsen, H. M., Muller, M., Van Der Graaf, Y., and Geerlings, M. I. (2012). APOE epsilon4 differentially influences change in memory performance depending on age. The smart-MR study. *Neurobiol. Aging* 33:832.e15-22. doi: 10.1016/j.neurobiolaging.2011.07.016
- Khan, W., Giampietro, V., Banaschewski, T., Barker, G. J., Bokde, A. L., Buchel, C., et al. (2017). A multi-cohort study of ApoE varepsilon4 and amyloid-beta effects on the hippocampus in Alzheimer's disease. *J. Alzheimers Dis.* 56, 1159–1174. doi: 10.3233/JAD-161097
- Kilpatrick, C., Murrice, V., Cook, M., Andrewes, D., Desmond, P., and Hopper, J. (1997). Degree of left hippocampal atrophy correlates with severity of neuropsychological deficits. *Seizure* 6, 213–218. doi: 10.1016/S1059-1311(97)80008-8
- Kukulja, J., Thiel, C. M., Eggermann, T., Zerres, K., and Fink, G. R. (2010). Medial temporal lobe dysfunction during encoding and retrieval of episodic memory in non-demented APOE epsilon4 carriers. *Neuroscience* 168, 487–497. doi: 10.1016/j.neuroscience.2010.03.044
- Lim, Y. Y., Williamson, R., Laws, S. M., Villemagne, V. L., Bourgeat, P., Fowler, C., et al. (2017). Effect of APOE genotype on amyloid deposition, brain volume, and memory in cognitively normal older individuals. *J. Alzheimers Dis.* 58, 1293–1302. doi: 10.3233/JAD-170072
- Liu, Y., Tan, L., Wang, H. F., Liu, Y., Hao, X. K., Tan, C. C., et al. (2016). Multiple effect of APOE genotype on clinical and neuroimaging biomarkers across Alzheimer's disease spectrum. *Mol. Neurobiol.* 53, 4539–4547. doi: 10.1007/s12035-015-9388-7
- McKhann, G. M., Knopman, D. S., Chertkow, H., Hyman, B. T., Jack, C. R Jr, Kawas, C. H., et al. (2011). The diagnosis of dementia due to Alzheimer's disease: recommendations from the national institute on aging-Alzheimer's association workgroups on diagnostic guidelines for Alzheimer's disease. *Alzheimers Dement.* 7, 263–269. doi: 10.1016/j.jalz.2011.03.005
- Petersen, R. C., Aisen, P. S., Beckett, L. A., Donohue, M. C., Gamst, A. C., Harvey, D. J., et al. (2010). Alzheimer's Disease Neuroimaging Initiative (ADNI): clinical characterization. *Neurology* 74, 201–209. doi: 10.1212/WNL.0b013e3181cb3e25
- Scheller, E., Peter, J., Schumacher, L. V., Lahr, J., Mader, I., Kaller, C. P., et al. (2017). APOE moderates compensatory recruitment of neuronal resources during working memory processing in healthy older adults. *Neurobiol. Aging* 56, 127–137. doi: 10.1016/j.neurobiolaging.2017.04.015
- Schmidt, M. (1996). *Rey Auditory Verbal Learning Test A Handbook*. Los Angeles, CA: Western Psychological Services.
- Tuminello, E. R., and Han, S. D. (2011). The apolipoprotein e antagonistic pleiotropy hypothesis: review and recommendations. *Int. J. Alzheimers Dis.* 2011:726197. doi: 10.4061/2011/726197
- Wechsler, D. (1987). *The Wechsler Memory Scale-Revised*. New York, NY: Psychological Corporation.
- Welsh-Bohmer, K. A., Ostbye, T., Sanders, L., Pieper, C. F., Hayden, K. M., Tschanz, J. T., et al. (2009). Neuropsychological performance in advanced age: influences of demographic factors and apolipoprotein E: findings from the cache county memory study. *Clin. Neuropsychol.* 23, 77–99. doi: 10.1080/13854040801894730
- Williams, G. C. (1957). Pleiotropy, natural selection, and the evolution of senescence. *Evolution* 11, 398–411. doi: 10.1111/j.1558-5646.1957.tb02911.x
- Ystad, M. A., Lundervold, A. J., Wehling, E., Espeseth, T., Rootwelt, H., Westlye, L. T., et al. (2009). Hippocampal volumes are important predictors for memory function in elderly women. *BMC Med. Imaging* 9:17. doi: 10.1186/1471-2342-9-17

Conflict of Interest Statement: The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

Copyright © 2019 Wang, Zhou, Ye, Lin, Zhang and the Alzheimer's Disease Neuroimaging Initiative. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.